Targeting HER2 — A Triumph of Science
Mené sur 885 patientes atteintes d'un cancer du sein HER2+ de stade avancé (durée médiane de suivi : 21 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement de première ligne combinant anbénitamab (un anticorps bispécifique ciblant HER2) et HB1801 (formulation de docétaxel lié à l'albumine) par rapport au traitement standard (docétaxel, trastuzumab et pertuzumab)
Scientific progress in oncology has been substantially advanced through mechanistic discovery. Human epidermal growth factor receptor 2 (HER2) was first established as an oncogenic driver by Slamon et al. in 1987, a discovery that catalyzed the development of highly effective, life-prolonging targeted therapies.1 Substantial progress has since been made in this once poor-prognosis subtype of advanced breast cancer, with numerous therapeutic agents showing clinical benefit through diverse mechanisms of action.2 For the past 14 years, the standard regimen for first-line treatment of HER2-positive advanced breast cancer has been established by the Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) trial.3 This . . .
New England Journal of Medicine , éditorial, 2026